Search Result

Results for "

safety profile

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (2) Adrenergic Receptor (2) Akt (1) Aminopeptidase (1) Anaplastic lymphoma kinase (ALK) (1) Apelin Receptor (APJ) (2) Apoptosis (3) Bacterial (4) CD276/B7-H3 (1) CD3 (1) CDK (1) Cholinesterase (ChE) (3) COX (1) CRFR (2) CXCR (1) Cytochrome P450 (1) Drug Metabolite (1) E1/E2/E3 Enzyme (1) EGFR (3) Endogenous Metabolite (4) Estrogen Receptor/ERR (1) Fluorescent Dye (1) Free Fatty Acid Receptor (1) Fungal (1) G protein-coupled Bile Acid Receptor 1 (1) Glycosidase (1) HCV (1) HIV (3) Insecticide (1) IRAK (1) Isocitrate Dehydrogenase (IDH) (2) Isotope-Labeled Compounds (4) Keap1-Nrf2 (1) LPL Receptor (5) mAChR (2) mGluR (1) Molecular Glues (1) Monoamine Oxidase (1) Neprilysin (1) Nucleoside Antimetabolite/Analog (3) Opioid Receptor (1) P2Y Receptor (1) Phosphatase (1) Phosphodiesterase (PDE) (1) Potassium Channel (1) PPAR (1) Reference Standards (4) Reverse Transcriptase (2) SARS-CoV (2) Sodium Channel (2) TAM Receptor (1) TGF-β Receptor (1) TNF Receptor (2) Topoisomerase (1) VEGFR (1) Virus Protease (1)
By Research Areas:	Cancer (19) Cardiovascular Disease (8) Endocrinology (2) Infection (11) Inflammation/Immunology (15) Metabolic Disease (7) Neurological Disease (8)

By Targets:

Adenosine Receptor (2)

Adrenergic Receptor (2)

Akt (1)

Aminopeptidase (1)

Anaplastic lymphoma kinase (ALK) (1)

Apelin Receptor (APJ) (2)

Apoptosis (3)

Bacterial (4)

CD276/B7-H3 (1)

CD3 (1)

CDK (1)

Cholinesterase (ChE) (3)

COX (1)

CRFR (2)

CXCR (1)

Cytochrome P450 (1)

Drug Metabolite (1)

E1/E2/E3 Enzyme (1)

EGFR (3)

Endogenous Metabolite (4)

Estrogen Receptor/ERR (1)

Fluorescent Dye (1)

Free Fatty Acid Receptor (1)

Fungal (1)

G protein-coupled Bile Acid Receptor 1 (1)

Glycosidase (1)

HCV (1)

HIV (3)

Insecticide (1)

IRAK (1)

Isocitrate Dehydrogenase (IDH) (2)

Isotope-Labeled Compounds (4)

Keap1-Nrf2 (1)

LPL Receptor (5)

mAChR (2)

mGluR (1)

Molecular Glues (1)

Monoamine Oxidase (1)

Neprilysin (1)

Nucleoside Antimetabolite/Analog (3)

Opioid Receptor (1)

P2Y Receptor (1)

Phosphatase (1)

Phosphodiesterase (PDE) (1)

Potassium Channel (1)

PPAR (1)

Reference Standards (4)

Reverse Transcriptase (2)

SARS-CoV (2)

Sodium Channel (2)

TAM Receptor (1)

TGF-β Receptor (1)

TNF Receptor (2)

Topoisomerase (1)

VEGFR (1)

Virus Protease (1)

By Research Areas:

Cancer (19)

Cardiovascular Disease (8)

Endocrinology (2)

Infection (11)

Inflammation/Immunology (15)

Metabolic Disease (7)

Neurological Disease (8)

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-114301

PF-06305591	Sodium Channel	Neurological Disease
PF-06305591 is a potent and highly selective voltage gated sodium channel NaV1.8 blocker, with an IC₅₀ of 15 nM. An excellent preclinical in vitro ADME and safety profile .

HY-114301A

PF-06305591 dihydrate	Sodium Channel	Neurological Disease
PF-06305591 dihydrate is a potent and highly selective voltage gated sodium channel NaV1.8 blocker, with an IC₅₀ of 15 nM. An excellent preclinical in vitro ADME and safety profile .

HY-161178

LK-60	Bacterial	Infection
LK-60 is a potent DprE1 inhibitor. LK-60 effectively inhibits the proliferation of Mycobacterium tuberculosis. LK-60 has good safety profiles to gut microbiota and human cells .

HY-111021

ASP-4058 1 Publications Verification	LPL Receptor	Inflammation/Immunology
ASP-4058 is a next-generation, selective and oral bioactive agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P₁ and S1P₅), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile .

HY-111021A

ASP-4058 hydrochloride 1 Publications Verification	LPL Receptor	Inflammation/Immunology
ASP-4058 hydrochloride is a next-generation, selective and orally active agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P₁ and S1P₅), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile .

HY-115494

Neladenoson dalanate hydrochloride Neladenoson bialanate hydrochloride; BAY-1067197 hydrochloride	Adenosine Receptor	Cardiovascular Disease
Neladenoson dalanate (Neladenoson bialanate; BAY-1067197) hydrochloride is a orally active agonist precursor of partial Adenosine A1 Receptor. Neladenoson dalanate hydrochloride has a good pharmacokinetic and safety profile, can be used for the chronic heart diseases .

HY-123353

Neladenoson dalanate Neladenoson bialanate; BAY-1067197	Adenosine Receptor	Cardiovascular Disease
Neladenoson dalanate (Neladenoson bialanate; BAY-1067197) is a orally active agonist precursor of partial Adenosine A1 Receptor. Neladenoson dalanate has a good pharmacokinetic and safety profile, can be used for the chronic heart diseases .

HY-14742

Faxeladol	Opioid Receptor	Others
Faxeladol is a compound with analgesic activity that reduced mean pain intensity compared with placebo in a suppression trial for painful polyneuropathy with a favorable safety profile.

HY-108711

GPR120 Agonist 1	Free Fatty Acid Receptor	Metabolic Disease
GPR120 Agonist 1 is a potent and selective GPR120 agonist, and possesses promising antidiabetic effect and good safety profile to be a development candidate .

HY-168140

TGR5 agonist 6	G protein-coupled Bile Acid Receptor 1	Cancer
TGR5 agonist 6 (compund 22b) is a non-systemic gut-targeted TGR5 agonist with significant and sustained blood sugar-lowering effects and an acceptable safety profile .

HY-163505

Anti-MRSA agent 11	Bacterial	Others
Anti-MRSA agent 11 suppresses fluoroquinolone-sensitive strain USA500 and -resistant MRSA isolate Mu50 (MIC =0.39 μg/mL). Anti-MRSA agent 11 displayes favorable in vivo half-life and safety profiles .

HY-105040

Pomaglumetad methionil LY2140023 hydrate	mGluR	Neurological Disease
Pomaglumetad methionil (LY2140023 hydrate) is an oral methionine prodrug of the potent specific mGlu2/3 receptor agonist LY404039 (HY-50906). Pomaglumetad methionil is well-tolerated and has a distinct safety profile, and can be used for schizophrenia .

HY-169223

Roxatidine hydrochloride	Endogenous Metabolite	Endocrinology
Roxatidine hydrochloride is an anti-ulcer compound with the activity of inhibiting gastric acid secretion. Roxatidine hydrochloride effectively inhibits duodenal and gastric ulcers and reduces ulcer pain. Roxatidine hydrochloride has a better safety profile than other similar compounds due to the lower dose required for effective inhibition .

HY-145285

APJ receptor agonist 5	Apelin Receptor (APJ)	Cardiovascular Disease
APJ receptor agonist 5 (compound 3) is a potent and orally active agonist of apelin receptor (APJ) with an EC₅₀ of 0.4 nM. APJ receptor agonist 5 displays excellent pharmacokinetic profiles in the rodent heart failure (HF) model. APJ receptor agonist 5 also shows an acceptable safety profile in preclinical toxicology studies. APJ receptor agonist 5 leads to improved cardiac function and can be used for researching the HF disease .

HY-113603

Tildacerfont SPR001; LY2371712	CRFR	Cancer
Tildacerfont is a potent and orally active corticotrophin-releasing factor type 1 (CRF1) receptort antagonis. Tildacerfont effectively reduces adrenocorticotropic hormone (ACTH) and adrenal androgen levels. Tildacerfont has favourable safety profile. Tildacerfont can be used for researching congenital adrenal hyperplasia .

HY-145284

APJ receptor agonist 4	Apelin Receptor (APJ)	Cardiovascular Disease
APJ receptor agonist 4 is a potent and orally active agonist of apelin receptor (APJ) with EC₅₀ and Ki of 0.06 nM and 0.07 nM respectively. APJ receptor agonist 4 displays excellent pharmacokinetic profiles in the rodent heart failure (HF) model. APJ receptor agonist 4 also shows an acceptable safety profile in preclinical toxicology studies. APJ receptor agonist 4 leads to improved cardiac function and can be used for researching the HF disease .

HY-115989

HCV-IN-38	HCV	Infection
HCV-IN-38 is a potent, selective and orally active HCV inhibitor (EC₅₀=15 nM, SI=431). HCV-IN-38 has high anti-HCV activity and low cytotoxicity. HCV-IN-38 has a good safety and oral pharmacokinetic profile .

HY-145311

Bis-Pro-5FU	Nucleoside Antimetabolite/Analog	Cancer
Bis-Pro-5FU (Compound 4) is a 5-FU precursor that confers oral bioavailability and increase the safety profile of 5-Fluorouracil (5-FU) chemotherapy regimens. 5-FU is an antineoplastic antimetabolite that is widely used for the research of colorectal and pancreatic cancer .

HY-156654

Ibuzatrelvir PF-07817883	SARS-CoV Virus Protease	Infection
Ibuzatrelvir (PF-07817883), a second-generation, orally bioavailable, is SARS-CoV-2 main protease (M ^pro and 3CL ^pro) inhibitor with improved metabolic stability. Ibuzatrelvir has demonstrated pan-human coronavirus antiviral activity and off-target selectivity profile in vitro and in preclinical animal studies. Ibuzatrelvir is well tolerated with a safety profile similar to placebo and prevents viral infection and transmission. Ibuzatrelvir can be used to inhibit COVID-19 .

HY-107784

Ectoine	Bacterial	Inflammation/Immunology
Ectoine is a natural cell protectant, an amino acid derivate produced by bacteria living under extremely harsh environmental conditions. Ectoine serves as an osmoregulatory compatible solute, increasing the hydration of the skin surface and stabilizing lipid layers, which is useful in skincare. Ectoine demonstrates a good safety profile for the treatment of allergic rhinitis .

HY-17552

sn-Glycero-3-phosphocholine 1 Publications Verification Choline Alfoscerate; Alpha-GPC; L-α-GPC	Cholinesterase (ChE) Endogenous Metabolite	Neurological Disease
sn-Glycero-3-phosphocholine (Choline Alfoscerate) is a precursor in the biosynthesis of brain phospholipids and increases the bioavailability of choline in nervous tissue. sn-Glycero-3-phosphocholine (Choline Alfoscerate) has significant effects on cognitive function with a good safety profile and tolerability, and is effective in the treatment of Alzheimer's disease and dementia .

HY-120802

Navafenterol AZD-8871; LAS191351	mAChR Adrenergic Receptor	Inflammation/Immunology
Navafenterol (AZD-8871) is an inhaled dual-acting, potent, selective, and long-lasting M3-antagonist/β2-agonist (MABA) with long-lasting effects and favorable safety profile. The pIC₅₀ is 9.5 for human M3 receptor, and the pEC₅₀ is 9.5 for β2-adrenoceptor. Navafenterol can be used for the research of chronic obstructive pulmonary disease (COPD). Bronchoprotective and antisialagogue effects. Favorable cardiovascular profile .

HY-18767

Ivosidenib Maximum Cited Publications 14 Publications Verification AG-120	Isocitrate Dehydrogenase (IDH)	Metabolic Disease Cancer
Ivosidenib (AG-120) is an orally active inhibitor of isocitrate dehydrogenase 1 mutant (mIDH1) enzyme, it exhibits profound d-2-hydroxyglutatrate (2-HG) lowering in vivo. Ivosidenib (AG-120) has the potential for AML therapy due to its acceptable safety profile and clinical activity .

HY-147698

ZLHQ-5f	CDK Topoisomerase Apoptosis	Cancer
ZLHQ-5f is a dual CDK2 and Topo I inhibitor with an IC₅₀ of 0.145 μM against CDK2/CycA2. ZLHQ-5f arrests the cell cycle in S-phase, triggers apoptosis in HCT116 cells, and has a good safety profile .

HY-149940

SIMR3030	SARS-CoV	Infection
SIMR3030 is a potent SARS-CoV-2 PLpro inhibitor with an IC₅₀ value of 0.0399 µg/mL. SIMR3030 shows antiviral activity. SIMR3030 decreases SARS-CoV spike, ORF1b, IFN-α, IL-6 mRNA expression. SIMR3030 exhibits a satisfactory safety profile in mice .

HY-120802A

Navafenterol saccharinate AZD-8871 saccharinate; LAS191351 saccharinate	mAChR Adrenergic Receptor	Infection Inflammation/Immunology
Navafenterol (AZD-8871) saccharinate is an inhaled dual-acting, potent, selective, and long-lasting M3-antagonist/β2-agonist (MABA) with long-lasting effects and favorable safety profile. The pIC₅₀ is 9.5 for human M3 receptor, and the pEC₅₀ is 9.5 for β2-adrenoceptor. Navafenterol saccharinate can be used for the research of chronic obstructive pulmonary disease (COPD). Bronchoprotective and antisialagogue effects. Favorable cardiovascular profile .

HY-100375

Diroximel fumarate 4 Publications Verification ALKS 8700; BIIB098	Keap1-Nrf2	Inflammation/Immunology
Diroximel fumarate (ALKS 8700) is an orally-active and well-tolerated monomethyl fumarate (MMF) proagent in a controlled-release formulation. Diroximel fumarate is considered as active equivalent to its active metabolite dimethyl fumarate (DMF). Diroximel fumarate has a favorable safety and efficacy profile, has the potential for the study of multiple sclerosis (MS). Diroximel fumarate is a Nrf2 activator that alleviate MGO-induced pain hypersensitivity .

HY-171612

Follitropin alfa, Lutropin alfa (2:1)	Estrogen Receptor/ERR	Endocrinology
Follitropin alfa, Lutropin alfa (2:1) is a combination of recombinant human follicle-stimulating hormone (Follitropin alfa, FSH) and recombinant human luteinizing hormone (Lutropin alfa, LH) in a 2:1 ratio. Follitropin alfa, Lutropin alfa (2:1) is a gonadotropin preparation used in assisted reproductive technology (ART) that is effective in achieving pregnancy with a good safety profile .

HY-155074

EGFR-IN-79	EGFR	Cancer
EGFR-IN-79 (compound 21) is an EGFR inhibior with antitumor activity. EGFR-IN-79 induces ROS-independent apoptosis and EGFR/AKT/mTOR-mediated autophagy. EGFR-IN-79 induces cell death at both proliferating and quiescent zones of EJ28 spheroids. EGFR-IN-79 exhibits safety profile in the zebrafish-based model .

HY-119530

Thiamiprine BW 57-323	Nucleoside Antimetabolite/Analog	Others
Thiamiprine (BW 57-323) is a compound related to azathioprine. Its nucleoside forms are similar to the parent compound in terms of cytotoxicity in vitro (except for the arabinoside). In the rat adjuvant arthritis model in vivo, its riboside and 2'-deoxyriboside are less active than the parent compound. The arabinoside is inactive and nontoxic. It has similar potency to the other parent compounds tested, but has a different safety profile.

HY-143330

MAO-B-IN-4	Monoamine Oxidase	Neurological Disease
MAO-B-IN-4 (Compound 26) is an orally active and reversible MAO-B inhibitor with an IC₅₀ of 9 nM. MAO-B-IN-4 has good metabolic stability, safety profile and brain permeability. MAO-B-IN-4 shows antidepressant activity in rats and mice. MAO-B-IN-4 can be used in studies related to Alzheimer's disease .

HY-151813

NNMT-IN-4	Fluorescent Dye	Cancer
NNMT-IN-4 (compound 38) is a selective, uncompetitive and membrane permeability nicotinamide N-methyltransferase (NNMT) inhibitor with IC₅₀ values of 42 and 38 nM in vitro biochemical and cell-based assays, respectively. NNMT-IN-4 shows favorable PK/PD and safety profiles as well as excellent oral bioavailability and pharmaceutical properties. NNMT-IN-4 can be used as a vivo chemical probe of NNMT .

HY-107784R

Ectoine (Standard)	Reference Standards Bacterial	Inflammation/Immunology
Ectoine (Standard) is the analytical standard of Ectoine. This product is intended for research and analytical applications. Ectoine is a natural cell protectant, an amino acid derivate produced by bacteria living under extremely harsh environmental conditions. Ectoine serves as an osmoregulatory compatible solute, increasing the hydration of the skin surface and stabilizing lipid layers, which is useful in skincare. Ectoine demonstrates a good safety profile for the treatment of allergic rhinitis .

HY-149844

S-F24	Fungal	Infection
S-F24 is an antifungal agent with excellent broad-spectrum. S-F24 inhibits CYP3A4 with an IC₅₀ value of 0.4 μM. S-F24 displays a good safety profile with high selectivity, low hemolytic effects, and low tendency to induce resistance. S-F24 can be used for research on fungal infections .

HY-151933

HIV-1 inhibitor-49	HIV Reverse Transcriptase	Infection
HIV-1 inhibitor-49 is an orally active HIV-1 inhibitor, is a HEPT analog. HIV-1 inhibitor-49 possesses great pharmacokinetics profiles and potent non-nucleoside reverse transcriptase inhibitory activity (IC₅₀=30 nM). HIV-1 inhibitor-49 exerts potential safety without acute toxicity in mouse model .

HY-174417

NNRT-IN-10	Reverse Transcriptase HIV Potassium Channel Cytochrome P450	Infection
NNRT-IN-10 is a potent, selective and orally active non-nucleoside HIV-1 reverse transcriptase (NNRTI) inhibitor with with an EC₅₀ values ranging from 1.16 to 18.3 nM for HIV and its mutant strains. NNRT-IN-10 exhibits good pharmacokinetic properties and favorable safety profiles. NNRT-IN-10 can be used for the study of AIDS, caused by HIV-1 .

HY-170961

SDUY816	Aminopeptidase Neprilysin	Neurological Disease
SDUY816 is an oral active dual APN/NEP inhibitor, with IC₅₀ values of 0.68 μM for APN and 6.9 μM for NEP. SDUY816 exhibits analgesic effects and demonstrates good safety and pharmacokinetic profiles, with an oral bioavailability of 27% and a half-life of 4.02 hours in rats (oral administration, 10 mg/kg). SDUY816 has potential applications in the research of neuropathic pain disorders .

HY-150550

COX-2-IN-26	COX	Inflammation/Immunology
COX-2-IN-26 is a potent, selective and orally active COX-2 inhibitor with IC₅₀ values of 10.61, 0.067, 1.96 µM for COX-1, COX-2, 15-LOX, respectively. COX-2-IN-26 shows anti-inflammatory activity. COX-2-IN-26 shows gastrointestinal safety profile .

HY-155518

IRAK4-IN-25	IRAK	Inflammation/Immunology
IRAK4-IN-25 (compound 38) is an orally acitve and potent IRAK4 inhibitor (IC₅₀=7.3 nM), with low clearance (Cl=12 mL/min/kg). IRAK4-IN-25 inhibits production of pro-inflammatory cytokines, and shows in vitro safety and ADME profiles. IRAK4-IN-25 can be used for research in inflammatory and autoimmune disorders .

HY-113603S

Tildacerfont-d8 SPR001-d₈; LY2371712-d₈	Isotope-Labeled Compounds CRFR	Cancer
Tildacerfont-d₈ (SPR001-d₈) is a deuterium labeled Tildacerfont (HY-113603). Tildacerfont is a potent and orally active corticotrophin-releasing factor type 1 (CRF1) receptort antagonis. Tildacerfont effectively reduces adrenocorticotropic hormone (ACTH) and adrenal androgen levels. Tildacerfont has favourable safety profile. Tildacerfont can be used for researching congenital adrenal hyperplasia .

HY-155489

DDO-2728 1 Publications Verification	Anaplastic lymphoma kinase (ALK) Apoptosis	Cancer
DDO-2728 (compound 19) is a selective AlkB homologue 5 (ALKBH5) inhibitor with an IC₅₀ of 2.97 μM. DDO-2728 increases the abundance of N ⁶ methyladenosine (m ⁶A) modifications, inducing cell apoptosis and cycle arrest. DDO-2728 suppresses tumor growth in the MV4 11 xenograft model with favorable safety profile, shows the potential of targeting ALKBH5 in cancer research .

HY-178175

Chitin synthase-IN-15	Insecticide	Infection
Chitin synthase-IN-15 (Compound 6k) is a chitin synthase inhibitor. Chitin synthase-IN-15 has insecticidal efficacy against Plutella xylostella, with LC₅₀ values of 0.789 and 0.951 μg/mL. Chitin synthase-IN-15 induces molting disruptions, larval mortality, and aberrant pupation, thereby effectively mitigating pest populations. Chitin synthase-IN-15 is an insecticidal agent with favorable ecological safety profiles .

HY-P99625

Frexalimab SAR441344; INX-021	TNF Receptor	Metabolic Disease Inflammation/Immunology
Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sj gren’s syndrome and type I diabetes research .

HY-P9989

Linvoseltamab REGN5458	CD3 TNF Receptor	Cancer
Linvoseltamab (REGN5458) is a bispecific T-cell engager (BiTE) antibody that specifically binds to B cell maturation antigen (BCMA) and CD3 of T cells, thereby directing T cells to multiple myeloma (MM) cells expressing BCMA and activating T cells to kill tumor cells. Linvoseltamab can be used in research of relapsed/refractory multiple myeloma (RRMM) .

HY-P99242

Alsevalimab 1 Publications Verification	CD276/B7-H3	Cancer
Alsevalimab is a humanized, afucosylated IgG1 monoclonal antibody against B7-H4. Alsevalimab blocks the binding of the B7-H4 protein to the receptors on the surface of T cells, reversing the immunosuppressive state in the tumor microenvironment, thereby activating the killing effect of T cells on cancer cells. Alsevalimab can be used in combination with Pembrolizumab (HY-P9902), and shows good safety profiles .

HY-119530R

Thiamiprine (Standard) BW 57-323 (Standard)	Nucleoside Antimetabolite/Analog Reference Standards	Others
Thiamiprine (Standard) is the analytical standard of Thiamiprine. This product is intended for research and analytical applications. Thiamiprine (BW 57-323) is a compound related to azathioprine. Its nucleoside forms are similar to the parent compound in terms of cytotoxicity in vitro (except for the arabinoside). In the rat adjuvant arthritis model in vivo, its riboside and 2'-deoxyriboside are less active than the parent compound. The arabinoside is inactive and nontoxic. It has similar potency to the other parent compounds tested, but has a different safety profile.

HY-111755

Oral antiplatelet agent 1	P2Y Receptor	Cardiovascular Disease
Oral antiplatelet agent 1 is a potent P2Y₁₂ receptor antagonist. Oral antiplatelet agent 1 exhibits excellent antiplatelet aggregation potency with an IC₅₀ value of 2.94 μM as well as antithrombotic efficacy in a rat ferric chloride model. Oral antiplatelet agent 1 shows a superior safety profile than Clopidogrel (HY-15283) in a rat tail-bleeding model. Oral antiplatelet agent 1 can be used to research thromboembolic disorders .

HY-119821R

Terphenyllin (Standard)	Reference Standards Glycosidase	Infection
Thiamiprine (Standard) is the analytical standard of Thiamiprine. This product is intended for research and analytical applications. Thiamiprine (BW 57-323) is a compound related to azathioprine. Its nucleoside forms are similar to the parent compound in terms of cytotoxicity in vitro (except for the arabinoside). In the rat adjuvant arthritis model in vivo, its riboside and 2'-deoxyriboside are less active than the parent compound. The arabinoside is inactive and nontoxic. It has similar potency to the other parent compounds tested, but has a different safety profile.

HY-18767S2

Ivosidenib-13C5 AG-120-¹³C₅	Isotope-Labeled Compounds Isocitrate Dehydrogenase (IDH)	Metabolic Disease Cancer
Ivosidenib- ¹³C₅ (AG-120- ¹³C₅) is ¹³C labeled Ivosidenib. Ivosidenib (AG-120) is an orally active inhibitor of isocitrate dehydrogenase 1 mutant (mIDH1) enzyme, it exhibits profound d-2-hydroxyglutatrate (2-HG) lowering in vivo. Ivosidenib (AG-120) has the potential for AML therapy due to its acceptable safety profile and clinical activity .

HY-18767S3

Ivosidenib-d5 AG-120-d₅	Isotope-Labeled Compounds	Metabolic Disease Cancer
Ivosidenib-d₅ (AG-120-d₅) is deuterium labeled Ivosidenib. Ivosidenib (AG-120) is an orally active inhibitor of isocitrate dehydrogenase 1 mutant (mIDH1) enzyme, it exhibits profound d-2-hydroxyglutatrate (2-HG) lowering in vivo. Ivosidenib (AG-120) has the potential for AML therapy due to its acceptable safety profile and clinical activity .

Cat. No.	Product Name

HY-L230

FDA Kinase Inhibitor Library

322 compounds

Kinases are enzymes that catalyze the addition of phosphate groups to substrate molecules, a process known as phosphorylation. Protein phosphorylation serves as a critical regulatory mechanism for numerous cellular processes, including cell division, metabolism, and signal transduction. The human genome encodes over 500 kinases, which collectively regulate approximately 50% of cellular functions. Due to their pivotal roles, kinases represent one of the most important target classes in drug development.

Kinase inhibitors can selectively block the activity of disease-associated kinases, making them valuable therapeutics for conditions such as cancer and inflammatory diseases. FDA-approved kinase inhibitors have undergone extensive preclinical and clinical studies, demonstrating high bioactivity, favorable safety profiles, and good bioavailability, rendering them suitable for investigating new therapeutic indications.

HY-L192

Dietary Supplement Library

71 compounds

Dietary supplement, also known as nutritional supplement or food supplement, include dietary components such as vitamins, minerals, and amino acids. The unique value of dietary supplement is particularly significant in the post-pandemic era. Compared to traditional medication, dietary supplement is often more readily accepted by the public due to their higher safety profile and the natural origin. By orally supplementing essential nutrients and bioactive substances, dietary supplement can help to enhance the body's health level and reduce the risk of diseases. For certain chronic conditions, proper dietary supplement can also serve as a powerful adjunct to conventional medical treatment, enhancing the effectiveness of medication.

MCE has included 71 dietary supplements, whose ingredients are all derived from the official lists published by authoritative organizations such as the FDA, EFSA, NMPA, etc. These compounds can be utilized in the development of health food products and for the mechanistic research of certain chronic diseases.

Cat. No.	Product Name	Target	Research Area

HY-P99625

Frexalimab SAR441344; INX-021	TNF Receptor	Metabolic Disease Inflammation/Immunology
Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sj gren’s syndrome and type I diabetes research .

HY-P9989

Linvoseltamab REGN5458	CD3 TNF Receptor	Cancer
Linvoseltamab (REGN5458) is a bispecific T-cell engager (BiTE) antibody that specifically binds to B cell maturation antigen (BCMA) and CD3 of T cells, thereby directing T cells to multiple myeloma (MM) cells expressing BCMA and activating T cells to kill tumor cells. Linvoseltamab can be used in research of relapsed/refractory multiple myeloma (RRMM) .

HY-P99242

Alsevalimab 1 Publications Verification	CD276/B7-H3	Cancer
Alsevalimab is a humanized, afucosylated IgG1 monoclonal antibody against B7-H4. Alsevalimab blocks the binding of the B7-H4 protein to the receptors on the surface of T cells, reversing the immunosuppressive state in the tumor microenvironment, thereby activating the killing effect of T cells on cancer cells. Alsevalimab can be used in combination with Pembrolizumab (HY-P9902), and shows good safety profiles .

HY-P99116

Faricimab RG7716; RO-6867461	VEGFR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-107784

Ectoine	Microorganisms Classification of Application Fields Source classification Amino acids Inflammation/Immunology Disease Research Fields	Bacterial
Ectoine is a natural cell protectant, an amino acid derivate produced by bacteria living under extremely harsh environmental conditions. Ectoine serves as an osmoregulatory compatible solute, increasing the hydration of the skin surface and stabilizing lipid layers, which is useful in skincare. Ectoine demonstrates a good safety profile for the treatment of allergic rhinitis .

HY-17552

sn-Glycero-3-phosphocholine 1 Publications Verification Choline Alfoscerate; Alpha-GPC; L-α-GPC	Natural Products Microorganisms Source classification Endogenous metabolite	Cholinesterase (ChE) Endogenous Metabolite
sn-Glycero-3-phosphocholine (Choline Alfoscerate) is a precursor in the biosynthesis of brain phospholipids and increases the bioavailability of choline in nervous tissue. sn-Glycero-3-phosphocholine (Choline Alfoscerate) has significant effects on cognitive function with a good safety profile and tolerability, and is effective in the treatment of Alzheimer's disease and dementia .

HY-107784R

Ectoine (Standard)	Microorganisms Source classification Amino acids	Reference Standards Bacterial
Ectoine (Standard) is the analytical standard of Ectoine. This product is intended for research and analytical applications. Ectoine is a natural cell protectant, an amino acid derivate produced by bacteria living under extremely harsh environmental conditions. Ectoine serves as an osmoregulatory compatible solute, increasing the hydration of the skin surface and stabilizing lipid layers, which is useful in skincare. Ectoine demonstrates a good safety profile for the treatment of allergic rhinitis .

HY-17552R

sn-Glycero-3-phosphocholine (Standard) Choline Alfoscerate (Standard); Alpha-GPC (Standard); L-α-GPC (Standard)	Natural Products Microorganisms Source classification Endogenous metabolite	Reference Standards Cholinesterase (ChE) Endogenous Metabolite
sn-Glycero-3-phosphocholine (Standard) is the analytical standard of sn-Glycero-3-phosphocholine. This product is intended for research and analytical applications. sn-Glycero-3-phosphocholine (Choline Alfoscerate) is a precursor in the biosynthesis of brain phospholipids and increases the bioavailability of choline in nervous tissue. sn-Glycero-3-phosphocholine (Choline Alfoscerate) has significant effects on cognitive function with a good safety profile and tolerability, and is effective in the treatment of Alzheimer's disease and dementia[1][2].

HY-119821R

Terphenyllin (Standard)	Microorganisms Source classification Phenols Polyphenols	Reference Standards Glycosidase
Thiamiprine (Standard) is the analytical standard of Thiamiprine. This product is intended for research and analytical applications. Thiamiprine (BW 57-323) is a compound related to azathioprine. Its nucleoside forms are similar to the parent compound in terms of cytotoxicity in vitro (except for the arabinoside). In the rat adjuvant arthritis model in vivo, its riboside and 2'-deoxyriboside are less active than the parent compound. The arabinoside is inactive and nontoxic. It has similar potency to the other parent compounds tested, but has a different safety profile.

Cat. No.	Product Name	Chemical Structure

HY-17552S

sn-Glycero-3-phosphocholine-d9

sn-Glycero-3-phosphocholine-d₉ is the deuterium labeled sn-Glycero-3-phosphocholine. sn-Glycero-3-phosphocholine (Choline Alfoscerate) is a precursor in the biosynthesis of brain phospholipids and increases the bioavailability of choline in nervous tissue. sn-Glycero-3-phosphocholine (Choline Alfoscerate) has significant effects on cognitive function with a good safety profile and tolerability, and is effective in the treatment of Alzheimer's disease and dementia .

HY-113603S

Tildacerfont-d8

Tildacerfont-d₈ (SPR001-d₈) is a deuterium labeled Tildacerfont (HY-113603). Tildacerfont is a potent and orally active corticotrophin-releasing factor type 1 (CRF1) receptort antagonis. Tildacerfont effectively reduces adrenocorticotropic hormone (ACTH) and adrenal androgen levels. Tildacerfont has favourable safety profile. Tildacerfont can be used for researching congenital adrenal hyperplasia .